文献速递肝病消化道肿瘤与早癌

接受规律监测的慢性乙型肝炎患者早期肝细胞癌检测失败的预测因素

Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance.
PubMed 文献 · Aliment Pharmacol Ther · 2018-02-28

研究纳入4590例肝功能良好的慢性乙型肝炎患者,每6个月接受超声和甲胎蛋白(AFP)分析监测,169例(3.68%)诊断肝细胞癌(HCC),其中35例(20.7%)初诊即为巴塞罗那临床肝癌(BCLC)B或C期。多因素分析显示肝硬化、AFP≥9 ng/mL和糖尿病是HCC检测失败的独立预测因素;另一模型纳入肝硬度(LS)值,LS≥11.7 kPa和AFP≥9 ng/mL为预测因素。

要点

  • 规律监测下HCC检测失败率不高(每人年0.8%,每次检测0.1%)。
  • 肝硬化(HR 3.078)、AFP≥9 ng/mL(HR 5.235)、糖尿病(HR 3.336)为检测失败独立预测因素。
  • 肝硬度≥11.7 kPa(HR 11.045)和AFP≥9 ng/mL(HR 4.802)为另一模型的预测因素。

核心结论

  • 在每6个月接受超声和AFP分析的慢性乙型肝炎患者中,HCC检测失败率不高(每人年0.8%,每次检测0.1%),但对晚期肝纤维化(临床肝硬化或LS值>11.7 kPa)、高AFP水平或糖尿病患者应仔细关注,这些患者易发生监测失败。

研究设计与样本

  • 纳入肝功能良好的慢性乙型肝炎患者,每6个月接受超声和AFP分析监测。
  • 共纳入4590例患者(平均年龄52.1岁;男性61.6%),169例(3.68%)诊断HCC,其中35例(20.7%)初诊为BCLC B或C期。
  • 采用Cox回归分析识别检测失败的预测因素,检测失败定义为初诊即为BCLC B或C期。

主要发现

  • HCC检测失败的累积发生率第1年为0.2%,第5年为1.3%。
  • 多因素分析显示肝硬化(HR 3.078;95%CI 1.389-6.821;P=0.006)、AFP≥9 ng/mL(HR 5.235;95%CI 2.307-11.957;P=0.010)、糖尿病(HR 3.336;95%CI 1.341-8.296;P=0.010)为检测失败的独立预测因素。
  • 另一纳入LS值的模型显示LS≥11.7 kPa(HR 11.045;95%CI 2.066-59.037;P=0.005)和AFP≥9 ng/mL(HR 4.802;95%CI 1.613-14.297;P=0.005)为检测失败的预测因素。

临床怎么用

  • 作者认为,对晚期肝纤维化(临床肝硬化或LS值>11.7 kPa)、高AFP水平或糖尿病的慢性乙型肝炎患者应仔细关注,这些患者易发生监测失败。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A proportion of chronic hepatitis B (CHB) patients are diagnosed with advanced hepatocellular carcinoma (HCC) despite regular surveillance. AIMS: To determine predictors for HCC detection failure in CHB patients who underwent regular surveillance. METHODS: CHB patients with well-preserved liver function, who underwent ultrasonography and alpha-foetoprotein (AFP) analysis every 6 months, were enrolled. Cox regression analysis was used to identify predictors for detection failure, defined as HCC initially diagnosed at Barcelona Clinic Liver Cancer (BCLC) stage B or C. RESULTS: Of the 4590 CHB patients (mean age, 52.1 years; men, 61.6%), 169 patients were diagnosed with HCC (3.68%) and 35 (20.7%) HCC patients were initially diagnosed with HCC BCLC stage B or C. The cumulative incidence of HCC detection failure was 0.2% at year 1 and 1.3% at year 5. Multivariate analyses indicated that cirrhosis (hazard ratio [HR], 3.078; 95% CI, 1.389-6.821; P = 0.006), AFP levels ≥9 ng/mL (HR, 5.235; 95% CI, 2.307-11.957; P = 0.010), and diabetes mellitus (HR, 3.336; 95% CI, 1.341-8.296; P = 0.010) were independent predictors of HCC detection failure. Another model that incorporated liver stiffness (LS) values identified LS values ≥11.7 kPa (HR, 11.045; 95% CI, 2.066-59.037; P = 0.005) and AFP levels ≥9 ng/mL (HR, 4.802; 95% CI, 1.613-14.297; P = 0.005) as predictors of detection failure. CONCLUSIONS: In CHB patients undergoing regular surveillance with ultrasonography and alpha-foetoprotein (AFP) analysis every 6 months, the HCC detection failure rate was not high (0.8% per person; 0.1% per test). However, careful attention should be paid in patients with advanced liver fibrosis (clinical cirrhosis or LS value >11.7 kPa), high AFP levels, or diabetes mellitus, who are prone to surveillance failure.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chon YE, Jung KS, Kim MJ, et al. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther. 2018. PMID: 29492988. doi:10.1111/apt.14578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。